Mersana Therapeutics (MRSN) Competitors $0.38 -0.03 (-6.54%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.39 +0.01 (+2.79%) As of 06:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. MNPR, ELDN, ESPR, VYGR, DERM, DMAC, OGI, CYBN, FDMT, and SLNShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), DiaMedica Therapeutics (DMAC), Organigram (OGI), Cybin (CYBN), 4D Molecular Therapeutics (FDMT), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Its Competitors Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Organigram Cybin 4D Molecular Therapeutics Silence Therapeutics Mersana Therapeutics (NASDAQ:MRSN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership. Do insiders and institutionals have more ownership in MRSN or MNPR? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, MRSN or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$34.01M1.39-$171.67M-$0.59-0.64Monopar TherapeuticsN/AN/A-$8.40M-$3.48-9.96 Do analysts rate MRSN or MNPR? Mersana Therapeutics presently has a consensus price target of $5.20, suggesting a potential upside of 1,266.98%. Monopar Therapeutics has a consensus price target of $55.33, suggesting a potential upside of 59.69%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is MRSN or MNPR more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Monopar Therapeutics' return on equity of -107.21% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% Monopar Therapeutics N/A -107.21%-87.57% Which has more risk & volatility, MRSN or MNPR? Mersana Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Does the MarketBeat Community favor MRSN or MNPR? Mersana Therapeutics received 211 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Monopar Therapeutics an outperform vote while only 66.58% of users gave Mersana Therapeutics an outperform vote. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes25766.58% Underperform Votes12933.42% Monopar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% Does the media prefer MRSN or MNPR? In the previous week, Monopar Therapeutics had 5 more articles in the media than Mersana Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 1 mentions for Mersana Therapeutics. Monopar Therapeutics' average media sentiment score of 1.05 beat Mersana Therapeutics' score of 0.47 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mersana Therapeutics Neutral Monopar Therapeutics Positive SummaryMersana Therapeutics beats Monopar Therapeutics on 10 of the 18 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.73M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-0.628.7827.1220.06Price / Sales1.39255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book1.236.557.064.70Net Income-$171.67M$143.93M$3.23B$247.88M7 Day Performance3.29%3.84%2.86%2.63%1 Month Performance5.49%11.20%9.07%6.36%1 Year Performance-83.28%4.18%31.45%14.05% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.195 of 5 stars$0.38-6.5%$5.20+1,267.0%-83.2%$50.73M$34.01M-0.62150Gap UpMNPRMonopar Therapeutics3.258 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.6468 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Positive NewsESPREsperion Therapeutics4.1016 of 5 stars$0.92+8.1%$6.25+580.4%-58.3%$182.07M$259.57M-1.44200Options VolumeAnalyst RevisionVYGRVoyager Therapeutics4.4313 of 5 stars$3.29+20.1%$13.39+307.0%-61.0%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionGap UpHigh Trading VolumeDERMJourney Medical2.3183 of 5 stars$7.81-3.1%$9.88+26.4%+21.7%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.3602 of 5 stars$4.17+1.5%$8.00+91.8%+54.4%$178.82MN/A-7.4520Short Interest ↑OGIOrganigram0.6508 of 5 stars$1.31-3.0%N/A-7.3%$175.39M$194.09M-3.45860Positive NewsGap UpCYBNCybin2.118 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550Analyst RevisionFDMT4D Molecular Therapeutics2.9912 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Positive NewsAnalyst ForecastAnalyst RevisionGap UpSLNSilence Therapeutics2.9132 of 5 stars$5.73-1.9%$33.83+490.5%-74.9%$171.50M$27.70M-3.65100Positive News Related Companies and Tools Related Companies MNPR Competitors ELDN Competitors ESPR Competitors VYGR Competitors DERM Competitors DMAC Competitors OGI Competitors CYBN Competitors FDMT Competitors SLN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRSN Stock Free MRSN Stock Alerts